|
Genzyme focuses its efforts on well-defined medical areas with serious, unmet
needs where breakthrough therapies and services can significantly improve
patients' lives. We currently provide more than 10 major marketed products
concentrated in five diverse medical areas, as well as in diagnostic products
and services.
|
 |
|
These products and services give patients and their physicians critical information for decision making, allowing
quicker, more appropriate treatment. Their importance will increase as therapies become more targeted and
personalized. In 2004, we added significantly to our oncology testing capabilities.
|
 |
|
We have world-renowned expertise in lysosomal storage disorders, rare genetic diseases
caused by missing enzymes. In late 2004, we filed for approval of Myozyme in Europe and
plan filings in the United States and Japan in 2005.
|
|
|
Renagel helps control phosphorus levels in kidney hemodialysis patients without adding calcium or metal.
We are now investigating additional therapies for patients with other stages and types of renal disease.
|
|
|
Marketed in more than 60 countries, Synvisc relieves the pain of osteoarthritis of the
knee. Carticel and MACI are unique cell therapies for articular knee cartilage injuries.
We are actively developing the next generations of these successful orthopaedics products.
|
|
|
Campath and Clolar address different forms of leukemia. We are committed to supporting
these products through studies of new therapeutic applications and in earlier-line
treatment for their approved indications. Thyrogen, our thyroid cancer diagnostic, has
now been approved for therapeutic use in Europe in combination with radioiodine, and we
anticipate U.S. approval in 2005.
|
|
|
Thymoglobulin is the standard of care in acute renal transplant rejection. We are
investigating its use in induction and bone marrow transplantation, together with its
application to other organs and to the treatment of immune-mediated diseases.
|
|
